Adherence to Long-Term Therapies - Evidence for Action
(2003; 211 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentAcknowledgements
View the documentScientific writers
View the documentIntroduction
View the documentTake-home messages
Close this folderSection I - Setting the scene
Open this folder and view contentsChapter I - Defining adherence
Open this folder and view contentsChapter II - The magnitude of the problem of poor adherence
Close this folderChapter III - How does poor adherence affect policy-makers and health managers?
View the document1. Diabetes
View the document2. Hypertension
View the document3. Asthma
View the document4. References
Open this folder and view contentsSection II - Improving adherence rates: guidance for countries
Open this folder and view contentsSection III - Disease-Specific Reviews
Open this folder and view contentsAnnexes
Open this folder and view contentsWhere to find a copy of this book

4. References

1. Rybacki JJ. Improving cardiovascular health in postmenopausal women by addressing medication adherence issues. Journal of the American Pharmaceutical Association, 2002, 42: 63-71.

2. Dunbar-Jacob J et al. Adherence in chronic disease. Annual Review of Nursing Research, 2000, 18: 48-90.

3. Liebl A et al. [Costs of type 2 diabetes in Germany. Results of the CODE-2 study.] [German] Deutsche Medizinische Wochenschrift, 2001, 126: 585-589.

4. Liebl A et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2 study. Experimental & Clinical Endocrinology & Diabetes, 2002, 110: 10-16.

5. Beckles GL et al. Population-based assessment of the level of care among adults with diabetes in the U.S. Diabetes Care, 1998, 21: 1432-1438.

6. Lustman PJ, Griffith LS, Clouse RE. Depression in adults with diabetes. Seminars in Clinical Neuropsychiatry, 1997, 2: 15-23.

7. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Archives of Internal Medicine, 2000, 27: 3278-3285.

8. Kangas T et al. Direct costs of health care of drug-treated diabetic patients in Finland in 1989. In: Kangas T. The Finndiab Report. Stakes, Research Reports 58, 1995.

9. Henriksson F et al. Direct medical costs for patients with type 2 diabetes in Sweden. Journal of Internal Medicine, 2000, 248: 387-396.

10. Herman WH, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care, 1998, 21 (Suppl 3): C19-C24.

11. Berenson GS et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. New England Journal of Medicine, 1998, 338: 1650-1656.

12. Thompson DW, Furlan AJ. Clinical epidemiology of stroke. Neurologic Clinics, 1996, 14: 309-315.

13. al Roomi KA, Heller RF, Wlodarczyk J. Hypertension control and the risk of myocardial infarction and stroke: a population-based study. Medical Journal of Australia, 1990, 153: 595-599.

14. Borghi C et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. American Journal of Hypertension, 1999, 12: 665-672.

15. Marmot MG, Poulter NR. Primary prevention of stroke. Lancet, 1992, 339: 344-347.

16. Burt VL et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988- 1991. Hypertension, 1995, 25: 305-313.

17. Heller RF et al. Blood pressure measurement in the United Kingdom Heart Disease Prevention Project. Journal of Epidemiology & Community Health, 1978, 32: 235-238.

18. Sulbaran T et al. Epidemiologic aspects of arterial hypertension in Maracaibo, Venezuela. Journal of Human Hypertension, 2000, 14 (Suppl 1): S6-S9.

19. Waeber B, Burnier M, Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? Journal of Cardiovascular Pharmacology, 2000, 35 (Suppl 3): S23-S26.

20. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Bethesda, MD, National High Blood Pressure Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. 1997.

21. Burt VL et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey 1988- 1991. Hypertension, 1995, 25: 305-313.

22. Hershey JC et al. Patient compliance with antihypertensive medication. American Journal of Public Health, 1980, 70: 1081-1089.

23. Luscher TF et al. Compliance in hypertension: facts and concepts. Journal of Hypertension, 1985, 3: 3-9.

24. Hughes DA et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Economics, 2001, 10: 601-615.

25. Morisky DE et al. Five-year blood pressure control and mortality following health education for hypertensive patients. American Journal of Public Health, 1983, 73: 153-162.

26. Psaty BM et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. Journal of the American Medical Association, 1990, 263: 1653-1657.

27. Spector SL et al. Compliance of patients with asthma with an experimental aerosolized medication: implications for controlled clinical trials. Journal of Allergy and Clinical Immunology. 1986;77: 6-70.

28. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Medical Care, 2001, 39: 599-615.

29. Piatrauskene I. [Hypertension: economic aspects.] [Russian] Sovetskoe Zdravookhranenie, 1991, 4: 22-25.

30. McCombs JS et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Medical Care, 1994, 32: 214-226.

31. Tulenbaev MZ et al. [Economic efficacy of implementing a program to control arterial hypertension among industrial workers.] [Russian] Terapevticheskii Arkhiv, 1987, 59: 50-52.

32. Rizzo JA, Abbott TA, III, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Economics, 1996, 5: 249-265.

33. Cerveri I et al. International variations in asthma treatment compliance: the results of the European Community Respiratory Health Survey (ECRHS). European Respiratory Journal, 1999, 14: 288-294.

34. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? Annals of Allergy, Asthma, & Immunology, 1997, 79: 177-185.

35. Reid D et al. Management and treatment perceptions among young adults with asthma in Melbourne: the Australian experience from the European Community Respiratory Health Survey. Respirology, 2000, 5: 281 - 287.

36. Pearson MH, Bucknall CE. Measuring clinical outcomes in asthma. London, Royal College of Physicians, 1999.

37. Dekker FW et al. Compliance with pulmonary medication in general practice. European Respiratory Journal, 1993, 6: 886-890.

38. Slack MK, Brooks AJ. Medication management issues for adolescents with asthma. American Journal of Health-System Pharmacy, 1995, 52: 1417-1421.

39. GINA Project (Global Initiative for Asthma). 2002,

40. Balkrishnan R, Christensen DB. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. Clinical Therapeutics, 2000, 22: 452-469.

41. Marion RJ, Creer TL, Reynolds RV. Direct and indirect costs associated with the management of childhood asthma. Annals of Allergy, 1985, 54: 31-34.

42. Mahapatra P. Social, economic and cultural aspects of asthma: an exploratory study in Andhra Pradesh, India. Hyderabad, India, Institute of Health Systems, 1993.


to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017